VIB4920 for lupus kidney inflammation not responding well enough
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed lupus diagnosis based on accepted medical classification rules (ACR/SLICC/EULAR).
- Your urine test shows significant kidney involvement: UPCR is at least 1.0 from a 24-hour urine collection.
- You had a kidney biopsy in the last 24 weeks showing active lupus nephritis types (Class III/IV and/or V with Class III/IV) plus an activity score of at least 1.
- You must be able and willing to sign consent and follow all study visits and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.
This trial tests a new treatment, UB-VV410, for people with active systemic lupus erythematosus (SLE) or lupus nephritis (kidney inflammation caused by lupus) that hasn't responded to standard treatments. It aims to see if this therapy can help control the disease.
This Phase 2 study tests whether LNP023 can improve outcomes and safety in people with active lupus nephritis (lupus-related kidney inflammation), class III or IV. It may help by targeting the ongoing immune activity that is damaging the kidneys.
This trial tests a new medicine called QLG1074 added to standard treatments for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if the combination helps control the disease better.
This trial tests a new drug called SIM0278 for people with active lupus nephritis (kidney inflammation caused by lupus). It aims to see if adding this drug to standard treatment is safe and helpful for controlling the disease.
This study tests whether combining two medications, belimumab and voclosporin, is safe and effective for treating a specific type of lupus that affects the kidneys (lupus nephritis). It may help people with active kidney inflammation who need better control of their disease.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.